Sumitomo Pharma Brand Guidelines: Doshomachi 1897, Dainippon & the Sumitomo Igeta

Twenty-one Doshomachi merchants and a Tokyo works.

Sumitomo Pharma dates its founding to 14 May 1897, when, the company says, 21 leading figures of the drug trade in Doshomachi, Osaka’s traditional medicine-merchant district, set up Osaka Pharmaceuticals. In 1898 it built a pharmaceutical plant at Ebie in Osaka and acquired the Dainippon Pharmaceutical Company of Tokyo, a public-private venture, taking its name as Dainippon Pharmaceutical Co., Ltd.

That Tokyo company was older. Japanese Wikipedia says it was planned in 1884 by Fukuhara Arinobu, Nagayo Sensai and Shinagawa Yajiro as a semi-governmental enterprise and opened for business in 1885, with the chemist Nagai Nagayoshi, then studying in Germany, recruited as chief engineer; English Wikipedia says it started with equipment imported from Germany and made drugs listed in the Japanese Pharmacopoeia. Nagai left in 1893. The ephedrine he had isolated stayed with the company: it lists the launch of Ephedrine “Nagai” as a bronchodilator in 1927.

Dainippon grew by acquisition and diversification. It acquired Osaka Pharmaceutical Testing in 1908 and started a chemical products business in 1914, the company says.

The war years are part of that history. In 1941 Dainippon launched methamphetamine under the name Philopon, at first as a non-prescription medicine, Japanese Wikipedia says. The United Nations’ Bulletin on Narcotics wrote in 1989 that during the Second World War Japan’s military, considering stimulants useful for pilots, the signal corps and civilian military workers on night shifts, increased their production markedly, and that after the war pharmaceutical companies sold stockpiles to the public. English Wikipedia, citing Nick Reding’s 2009 book Methland, says Dainippon’s Philopon was sold for civilian and military use. Japan’s Stimulants Control Law of 1951 restricted the drug to limited medical and research use. The sources used for this guide do not say whether forced or conscripted labour was used at Dainippon’s sites during the war.

Dainippon after the war, and Sumitomo’s drug arm.

After the war Dainippon spread into veterinary drugs in 1950, non-prescription medicines in 1956 and food additives in 1960, the company says, and it built the Suzuka Plant in Mie Prefecture in 1968. In 1958 it launched a sleeping pill, Isomin, which contained thalidomide and was linked to birth defects in Japan’s thalidomide drug-injury case, Japanese Wikipedia says; the company’s history records a voluntary recall of its thalidomide preparation in 1962.

The Marupi mark was Dainippon’s emblem: a circle and a letter P. Japanese Wikipedia says the circle stood for the rising-sun flag and the P for “pharmacy,” and that the mark had begun as the trademark of an earlier Dainippon partnership.

The second half of the company came from the Sumitomo group. Sumitomo Pharmaceuticals was established in 1984 from the research, development and manufacturing divisions of Sumitomo Chemical’s pharmaceuticals business and the pharmaceutical sales division of Inabata & Co., Sumitomo Chemical’s sole distributor for its drugs, the company says. It used the Sumitomo igeta, a well-frame mark, as its emblem, Japanese Wikipedia says.

On 1 October 2005 the two merged, with Dainippon as the surviving company, to form Dainippon Sumitomo Pharma. Both old marks were set aside for a new one, a “green prism” based on light, according to Japanese Wikipedia. In 2014 the English name was reordered to Sumitomo Dainippon Pharma, and in 2015, on the merger’s tenth anniversary, the company adopted the global slogan “Innovation today, healthier tomorrows.”

Design and documentation.

Japanese drug makers tend to present themselves through places and archives as much as through products. Research campuses carry much of the weight: Chugai began full operation of its Chugai Life Science Park Yokohama, in Kanagawa, in 2023, and earlier ran a research laboratory at Tsukuba, in Ibaraki, from 2001 to 2005; Otsuka Pharmaceutical opened an Osaka Research Center for Drug Discovery in 2022, according to the companies’ own timelines. Photographs of laboratories, glass façades and scientists at screens recur across their websites and reports.

History is the other recurring theme. Several of these companies trace their roots to the Meiji and Taisho eras, and their anniversary pages lean on archive photographs of early shopfronts, factories and founders, including the old medicine-trading streets of Doshomachi in Osaka. Chugai marked its 100th anniversary in March 2025 and the Otsuka group its centenary in 2021, and both publish detailed chronologies of how their names and symbols changed.

The visual language is mostly cool and clean. Blue and white dominate packaging and corporate marks: Chugai moved its corporate colour from green to blue in 2002, and Otsuka describes the large O of its group symbol in “Otsuka BLUE.” Alongside prescription medicines, many of these firms sell consumer products, such as health drinks, eye drops and nutrition bars, that put their names on pharmacy and convenience-store shelves; Otsuka’s Pocari Sweat, launched in 1980, is one example.

Trade shows complete the picture: booths at international partnering events such as BIO and at CPHI Japan show the companies to licensing partners and suppliers rather than to shoppers. This guide sets out what can be checked about each company — its founding, its owners, its war years and its symbols — and marks clearly what rests only on the company’s own word.

From a green prism back to the well frame.

The merged company went abroad on a large scale. It bought the American company Sepracor in 2009 and renamed it Sunovion in 2010, English Wikipedia says, and the company says it entered oncology in 2012 by buying Boston Biomedical. In 2019 it agreed a strategic alliance with Roivant Sciences that brought several Roivant subsidiaries into the group; English Wikipedia says it agreed in October 2022 to buy the rest of one of them, Myovant, and in 2023 its American businesses were combined as Sumitomo Pharma America.

On 1 April 2022 the company changed its name to Sumitomo Pharma Co., Ltd., saying it wanted to refresh the group’s identity under the globally recognised Sumitomo brand. With the new name the green prism gave way to the Sumitomo igeta mark; the corporate colour stayed green but was renamed from DSP green to SMP green, and the English logo lettering was carried over, Japanese Wikipedia says. Sumitomo Chemical has held a majority since the 2005 merger, according to English Wikipedia.

Since then the group has narrowed. It sold its food and chemical subsidiary and its animal health subsidiary in 2023, and in 2025 moved its regenerative medicine business into joint ventures controlled by Sumitomo Chemical, Japanese Wikipedia says. On 1 April 2025 the company announced that its Asian business would move into a new company, 60 percent of which would go to Marubeni Global Pharma; that part was completed on 31 July 2025, Japanese Wikipedia says. The company said the remaining 40 percent is scheduled to pass to Marubeni Global Pharma under a shareholders’ agreement; that transfer was announced on 1 April 2025 and had not been completed at the time of writing.

The company has head offices in Doshomachi, Osaka, and Nihonbashi, Tokyo. Japanese Wikipedia lists its plants at Suzuka and Oita, and the company says its Osaka plant was closed and merged into Suzuka in 2003. It also says it completed SMaRT, a manufacturing plant for regenerative medicine and cell therapy, at its Central Research Laboratories in 2018.

For a design guide, Sumitomo Pharma shows how a merged company can return to its parent’s emblem. Compare Takeda, another drug house with roots in Doshomachi, and Daiichi Sankyo, a merger of two older drug makers. For this guide we use a forest green, paper and a bronze with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Sumitomo Pharma’s identity on hand — save it to a board in the Made Good inspiration library.